key: cord-0016787-ve3z0026
authors: Costa, Rafaella R.; Oliveira-da-Silva, João A.; Reis, Thiago A. R.; Tavares, Grasiele S. V.; Mendonça, Débora V. C.; Freitas, Camila S.; Lage, Daniela P.; Martins, Vívian T.; Antinarelli, Luciana M. R.; Machado, Amanda S.; Bandeira, Raquel S.; Ludolf, Fernanda; Santos, Thaís T. O.; Brito, Rory C. F.; Humbert, Maria V.; Menezes-Souza, Daniel; Duarte, Mariana C.; Chávez-Fumagalli, Miguel A.; Roatt, Bruno M.; Coimbra, Elaine S.; Coelho, Eduardo A. F.
title: Acarbose presents in vitro and in vivo antileishmanial activity against Leishmania infantum and is a promising therapeutic candidate against visceral leishmaniasis
date: 2021-04-18
journal: Med Microbiol Immunol
DOI: 10.1007/s00430-021-00707-4
sha: e51e133b9cb7cf8bdc97cb3d8ef618c3ab514cf2
doc_id: 16787
cord_uid: ve3z0026

Treatment against visceral leishmaniasis (VL) is mainly hampered by drug toxicity, long treatment regimens and/or high costs. Thus, the identification of novel and low-cost antileishmanial agents is urgent. Acarbose (ACA) is a specific inhibitor of glucosidase-like proteins, which has been used for treating diabetes. In the present study, we show that this molecule also presents in vitro and in vivo specific antileishmanial activity against Leishmania infantum. Results showed an in vitro direct action against L. infantum promastigotes and amastigotes, and low toxicity to mammalian cells. In addition, in vivo experiments performed using free ACA or incorporated in a Pluronic(®) F127-based polymeric micelle system called ACA/Mic proved effective for the treatment of L. infantum-infected BALB/c mice. Treated animals presented significant reductions in the parasite load in their spleens, livers, bone marrows and draining lymph nodes when compared to the controls, as well as the development of antileishmanial Th1-type humoral and cellular responses based on high levels of IFN-γ, IL-12, TNF-α, GM-CSF, nitrite and IgG2a isotype antibodies. In addition, ACA or ACA-treated animals suffered from low organ toxicity. Treatment with ACA/Mic outperformed treatments using either Miltefosine or free ACA based on parasitological and immunological evaluations performed one and 15 days post-therapy. In conclusion, data suggest that the ACA/Mic is a potential therapeutic agent against L. infantum and merits further consideration for VL treatment.

Leishmaniasis is a disease complex found in 98 countries in the world, where approximately 380 million people are susceptible to the infection by the Leishmania parasites, which are obligate intracellular pathogens able to invade phagocytic cells of the mammalian hosts [56] . Approximately 20 parasite species cause disease in humans, and clinical manifestations include visceral and tegumentary leishmaniasis [7, 20] . Visceral leishmaniasis (VL) is caused by Leishmania infantum and L. donovani species, being fever, anemia, wasting, hepatosplenomegaly and patient's immune suppression the clinical manifestations of active disease. VL is almost always fatal, if acute and left untreated [4] .

Treatment against VL relies on the use of pentavalent antimonials. However, drug toxicity, parenteral administration and long therapy regimens represent significant hindrances to effective treatment. In addition, parasite resistance has been reported, being this a main cause for relapse of infections in affected patients [9, 50] . Alternatively to pentavalent antimony compounds, Amphotericin B (AmpB) has been extensively used to treat VL. However, although it is highly effective against parasites, it is also toxic to the patient, causing nephrotoxicity, hypokalemia and myocarditis, among others [31] . AmpB-based liposomal formulations have minimized the side effects caused by treatment with the free drug, but its high cost prevents it from becoming a widespread therapeutic agent [51] . Paromomycin has also been used against Leishmania infection; however, this drug targets a relatively restricted range of Leishmania species and parasite resistance has been reported [38] . Moreover, Miltefosine, which was originally described as an anti-tumor agent, presents antileishmanial potential against distinct parasite species by inhibiting the biosynthesis of the glycosyl-phosphatidyl-inositol receptor, a key molecule for Leishmania intracellular survival [27, 36, 58] . However, miltefosine causes teratogenicity and parasitic resistance to this drug has also been described, thus limiting its clinical application [50] .

In this context, the identification of new antileishmanial agents is a challenge that remains to be overcome. Recently, a Leishmania proteome mining strategy was performed to select new drug targets against the parasites. Good drug candidates should be relevant for Leishmania survival within its mammalian hosts but should present low homology to human proteins [10] . In that study, a hypothetical protein, which was functionally annotated as a glucosidase-like protein and associated with Leishmania N-Glycan biosynthesis metabolic pathway, came up as a promising candidate. This parasite protein was also predicted to be potential target of two specific inhibitors, Acarbose (ACA) and Miglitol. The authors tested Miglitol against L. amazonensis and L. infantum, proving its effectiveness against both Leishmania species. Treatment with Miglitol significantly reduced the percentage of infection and number of recovered amastigotes from infected macrophages. Therefore, the authors recommended the use of Miglitol as a potential candidate to treat VL [10] . ACA is a specific inhibitor of glucosidase-like proteins. Administration of ACA causes a significant decrease in the plasma glucose levels of patients and thus, this drug has been used effectively to treat type-2-diabetes [21, 22] . In addition, to the best of our knowledge, there are no reports on the antileishmanial activity of ACA.

Poloxamer-based micelle systems have been explored to improve the efficacy of old drugs and/or reduce their toxicity [15, 28] . In addition, they have been also used to potentiate the properties of new antileishmanial agents [29, 42, 54] . Poloxamers are thermo-reversible and nonionic surfactant co-polymers that present amphiphilic nature consisting of hydrophilic and hydrophobic segments. They are easily manufactured, present low production cost, good stability and efficient targeting ability [34, 54] . Regarding immunological aspects, Poloxamer-based micelles have shown adjuvant effect by stimulating the development of a Leishmania-specific Th1-type response, when antileishmanial targets are in vivo tested against infection by the parasites [15, 25, 53] . In this context, in the present study, a ACA-carrying delivery system based on polymeric micelles was evaluated to treat against L. infantum infection.

The immunity for VL has been studied and resistance against infection involves the induction of the T-helper 1 (Th1) cell response based on the activation of CD4 + and CD8 + T cells, with concomitant production of cytokines such as IFN-γ, IL-12 and GM-CSF, among others. On the other hand, susceptibility to infection is related to the production of Th2-type profile cytokines, such as IL-4, IL-5 and IL-10, among others [14, 24] . Based on this understanding about the immunological mechanisms of leishmaniasis, distinct agents have been evaluated regarding their antileishmanial immunity, however, little progress has been made beyond the experimental stage [39, 55, 59] .

In the present study, ACA was evaluated in vitro and in vivo against L. infantum species. The free molecule or incorporated into a Poloxamer 407 (Pluronic ® F127)-based polymeric micelle system (ACA/Mic) was used to treat L. infantum-infected mice, and Miltefosine was used as a control drug. Parasitological, immunological and toxicological evaluations were performed one and 15 days post-treatment. Results showed that treatment using ACA or ACA/Mic induced a polarized and specific antileishmanial Th1-type immune response, which was reflected by significant reductions in the parasite load in the spleen, liver, bone marrow

The 50% Leishmania inhibitory concentration (IC 50 ) was evaluated by incubating L. infantum stationary promastigotes in the absence or presence of ACA (0 to 100.0 µg/mL) or AmpB (0 to 10.0 µg/mL), which was used as a control, in 96-well culture plates (Nunc, Nunclon, Roskilde, Denmark) for 48 h at 24 °C. Cell viability was assessed by 3-(4.5-dimethylthiazol-2-yl)-2.5-diphenyl tetrazolium bromide (Sigma-Aldrich, USA) method. The optical density (OD) values were read in a microplate spectrophotometer (Molecular Devices, Spectra Max Plus, San Jose, CA, USA) at 570 nm. Results were entered into Microsoft Excel (version 10.0) spreadsheets and IC 50 values were calculated by sigmoidal regression of the dose-response curves [52] .

ACA cytotoxicity to murine macrophages (CC 50 ) and red blood cells (RBC 50 ) was evaluated by determining the compound's concentration required for 50% reduction of cell viability. To evaluate the CC 50 , macrophages derived from female BALB/c mice were obtained by peritoneal lavage with 5 mL cold PBS pH 7.4. Peritoneal exudate cells were centrifuged at 1000×g for 10 min and resuspended in RPMI 1640 medium. Cells (5 × 10 5 per well) were then incubated in the absence of presence of ACA (0 to 100.0 µg/mL) or AmpB (0 to 10.0 µg/mL) for 48 h at 37 °C in 5% CO 2 . Macrophage viability was assessed by MTT method. To evaluate the RBC 50 , a 5% (v/v) human red blood cells suspension was incubated in the absence of presence of ACA (0 to 100.0 µg/ mL) or AmpB (0 to 10.0 µg/mL) for 1 h at 37 °C in 5% CO 2 when the suspension was centrifuged for 10 min at 1000×g and lysis percentage was determined spectrophotometrically at 570 nm. The absence of (blank) or 100% hemolysis were determined by replacing ACA or AmpB with an equal volume of phosphate-buffered saline pH 7.4 (PBS) or distilled water, respectively. CC 50 and RBC 50 values were calculated by sigmoidal regression of dose-response curves with Microsoft Excel software (version 10.0) [29] .

ACA efficacy for treatment of murine cells was evaluated in vitro by incubating macrophages (5 × 10 5 ) in RPMI 1640 medium supplemented with 20% FBS and 20 mM l-glutamine pH 7.4, for 24 h at 37 °C in 5% CO 2 . Parasites (5 × 10 6 cells) were then added to the wells and cultures were incubated for 48 h at 37 °C in 5% CO 2 . Free parasites were removed by extensive washing with medium. Infected macrophages were then left untreated or treated with ACA (0, 2.5, 5.0 and 10.0 µg/mL) or AmpB (0, 0.25, 0.5 and 1.0 µg/ mL) for 48 h at 37 °C in 5% CO 2 . After fixation with 4% (w/v) paraformaldehyde, cells were washed and stained with Giemsa. Percentage of infected macrophages, infectiveness reduction and number of amastigotes per macrophage were determined by counting 200 cells, in triplicate, using an optical microscope [29] .

Stationary promastigotes (5 × 10 6 cells) were incubated in the absence or presence of ACA (0, 2.5, 5.0 and 10.0 µg/ mL) or AmpB (0, 0.25, 0.5 and 1.0 µg/mL), for 4 h at 24 °C. Parasites were washed three times in RPMI 1640, quantified and used to infect macrophages at a ratio of 10 parasites per one macrophage for 24 h at 37 °C in 5% CO 2 . After fixation with 4% (w/v) paraformaldehyde, cells were washed and stained with Giemsa. Percentage of infected macrophages, reduction of infection and number of amastigotes per macrophage were determined by counting 200 cells, in triplicate, using an optical microscope [54] .

Stationary promastigotes (10 7 cells) were cultured in the absence or presence of ACA (0.35 and 0.70 μg/mL, corresponding to one and two times the IC 50 values, respectively) for 24 h at 25 °C. Parasites were washed in PBS and incubated with 500 nM MitoTracker Red CM-H2XROS (Invitrogen, USA) for 30 min in the dark and at room temperature. After washing twice with PBS, samples were added to a black 96-well plate and fluorescence intensity was measured using a fluorometer (FL×800, BioTek Instruments, Inc., Winooski, VT, USA) with excitation and emission wavelengths of 528 nm and 600 nm, respectively. Parasites incubated with carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazon (FCCP; 5.0 µM, Sigma-Aldrich, USA) for 10 min were used as control [54] .

Stationary promastigotes (10 7 cells) were cultured in the absence or presence of ACA (0.35 and 0.70 μg/mL, corresponding to one and two times the IC 50 values, respectively) for 24 h at 25 °C. Parasites were incubated with 20 µM cell-permeant 2′,7′-dichlorodihydrofluorescein diacetate (H 2 DCFDA; Sigma-Aldrich, USA) for 30 min in the dark and at room temperature. Fluorescence intensity was measured in a spectrofluorometer (Varioskan ® Flash, Thermo Scientific, USA) with excitation and emission wavelengths of 485 and 528 nm, respectively. H 2 O 2 -treated parasites (4.0 mM) were used as control [54] .

Stationary promastigotes (10 7 cells) were cultured in the absence or presence of ACA (0.35 and 0.70 μg/mL, corresponding to one and two times the IC 50 values, respectively) for 24 h at 25 °C. Parasites were incubated with Nile Red (1.0 μg/mL; Sigma-Aldrich, USA) for 30 min in the dark and at room temperature. Fluorescence intensity was measured in a spectrofluorometer (Varioskan ® Flash, Thermo Scientific, USA), with excitation and emission wavelengths of 485 and 528 nm, respectively [2] .

ACA-containing micelles (ACA/Mic) were prepared as described previously [29] . Briefly, Poloxamer 407 (18% w/w) was diluted in PBS under magnetic agitation for 18 h at 4 °C. 8 mg of ACA were added to 500 µL of dichloromethane and solubilized using a vortex. The mixture was then added to the Poloxamer solution under vigorous magnetic agitation in an ice bath until a viscous emulsion was obtained. The dichloromethane was evaporated using a rotary evaporator (Buchi, Flawil, Switzerland) and the ACAcontaining micelles were obtained as a transparent yellow gel at room temperature. Empty micelles were similarly prepared using 18% w/w Poloxamer 407 without the addition of ACA.

Mice (n = 12 per group) were infected subcutaneously with 10 7 L. infantum stationary promastigotes injected into their right hind footpad according to previously described [28, 42, 54] . Sixty days post-infection, infected mice were administered with saline alone (50 μL, PBS); empty micelles (50 μL, B/Mic: 10 mg/kg body weight); Miltefosine (50 μL, 2 mg/kg body weight); free ACA (50 μL, 5 mg/kg body weight); or ACA-containing micelles (50 μL, ACA/Mic: 5 mg/kg body weight). Except for Miltefosine which was administered by oral route, all other compounds were administered subcutaneously, every 2 days for a period of 10 days. Half of the animals were euthanized one and 15 days post-treatment, after which parasitological and immunological evaluations were performed.

Anti-parasite IgG1 and IgG2a isotype antibody levels were evaluated by ELISA assay in sera samples from infected and treated mice collected one and 15 days post-treatment. Briefly, L. infantum Soluble Leishmania Antigen (SLA) was used as the coating antigen (1.0 µg/well) and sera samples were diluted 1:100 in PBS-T (PBS plus 0.05% (v/v) Tween 20). Anti-mouse IgG1 and IgG2a horseradish-peroxidase conjugated antibodies (Sigma-Aldrich, USA) were used both at a 1:10,000 dilution in PBS-T. Reactions were developed in the presence of H 2 O 2 , ortho-phenylenediamine and citrate-phosphate buffer pH 5.0 for 30 min and in the dark. Next, reactions were stopped by addition of 2 N H 2 SO 4 , after which OD values were measured at 492 nm in an ELISA microplate spectrophotometer (Molecular Devices, Spectra Max Plus, Canada).

Spleens of infected and treated mice were collected one and 15 days post-treatment, when splenocytes were plated in 24-well plates (Nunc) and incubated in DMEM supplemented with 20% FBS and 20 mM l-glutamine at a pH 7.4. Cells (5 × 10 6 /mL) were unstimulated (medium) or stimulated with L. infantum SLA (50 μg/mL) for 48 h at 37 °C in 5% CO 2 . IFN-γ, IL-4, IL-10, IL-12p70 and GM-CSF levels were measured in the culture supernatants by capture ELISA assay (BD Pharmingen ® , San Diego, CA, USA), according to the manufacturer's instructions. Nitrite production was also evaluated in the same cellular supernatants by Griess reaction. To investigate the participation of T cells in the IFN-γ production in the Miltefosine-, ACA-or ACA/Mictreated mice, splenocytes (5 × 10 6 /mL) were unstimulated (medium), stimulated with L. infantum SLA (50 μg/mL; control) or stimulated and incubated with anti-CD4 (GK 1.5) or anti-CD8 (53-6.7) monoclonal antibody (5 μg each; Pharmingen ® , USA), for 48 h at 37 °C in 5% CO 2 . In all cases, cell supernatants were collected after 48 h incubation and used to quantify IFN-γ cytokine. Appropriate isotypematched controls [rat IgG2a (R35-95) and rat IgG2b (95-1)] were used [29] . IFN-γ, TNF-α and IL-10-producing CD4 + and CD8 + T cell profiles were evaluated in Miltefosine-, ACA-or ACA/Mic-treated mice by flow cytometry technique using the animals' spleens collected 15 days posttreatment. Briefly, spleen cells (5 × 10 6 /mL) were cultured in RPMI 1640 medium and then either stimulated with SLA (50 μg/mL) or left untreated for 48 h at 37 °C in 5% CO 2 .

IFN-γ, TNF-α and IL-10 cytokines were also evaluated in the spleen cells of the infected animals by flow cytometry technique. For this, splenocytes were incubated in the presence of 200 μL of RPMI medium in 96-well round-bottom culture plates at a concentration of 5 × 10 5 cells per well. Cells were unstimulated (medium) or stimulated with L. infantum SLA (20.0 μg/mL) for 48 h at 37 °C with 5% CO 2 . Cells were incubated with phorbol myristate acetate (5.0 ng/ mL), ionomycin (1.0 μg/mL) or lipopolysaccharide (0.01 μg/ uL), diluted in complete RPMI medium. Afterwards, cells were treated with Brefeldin A (10.0 μg/mL) for 4 h, and stained with Fixable Viability Stain 450 (BD Biosciences) for 15 min at room temperature, followed by anti-mouse CD3 FITC (clone 145.2C11), anti-mouse CD4 BV605 (clone RM4-5) or anti-mouse CD8α PerCP Cy5.5 (clone 53-6.7) (BD Biosciences Bioscience, USA), for 30 min at room temperature [6] . Next, fixation (FACS fixing solution), washing and permeabilization were performed. Permeabilized cells were then stained with anti-mouse IFN-γ AF700 (clone XMG1.2), anti-mouse TNF-α PE-Cy7 (clone LG.3A10) or anti-mouse IL-10 APC (JES5-16E) (BD Biosciences Bioscience, USA). Cells were acquired (100,000 events) on LSR Fortessa cytometer (BD Biosciences, USA) using FACSDiva software. For analysis in FlowJo software, dead cells were excluded after FVS450 stain and viable cells were gated for stained CD3 + CD4 + and CD3 + CD8 + cells and intracellular cytokine production. Results were expressed as percentage of CD4 + and CD8 + T cells in the SLA-stimulated cultures.

Parasite load was estimated in spleen, liver, bone marrow (BM) and draining lymph nodes (dLN) of infected and treated animals, one and 15 days post-treatment. Briefly, organs were macerated in a glass tissue grinder using sterile PBS, and tissue debris was removed by centrifugation at 150×g. Cells were then concentrated by centrifugation at 2000×g, pellets were resuspended in 1 mL of complete Schneider's medium and serially diluted using the same medium (10 -1 to 10 -12 dilutions). Each sample was plated in triplicate and analyzed after 7 days of having set up the cultures, at 24 °C. Results were expressed as the negative log of the titer (the dilution corresponding to the last positive well) adjusted per milligram of the organ. The parasitism in the animals' spleens was evaluated also by the quantitative PCR (qPCR) technique [3] . Briefly, spleen DNA was extracted using Wizard Genomic DNA Purification Kit (Promega Corporation) and resuspended in milli-Q water. The parasite load was estimated using specific primers to amplify L. infantum kDNA: Forward (5′-CCT ATT TTA CAC CAA CCC CCAGT-3′) and Reverse (5′-GGG TAG GGG CGT TCT GCG AAA-3′). Mouse gene encoding for β-actin (Forward: 5′-CAG AGC AAG AGA GGT ATC C-3′; Reverse: 5′-TCA TTG TAG AAG GTG TGG TGC-3′) was used as a control. Standard curves for kDNA and β-actin were obtained from DNA extracted from 1 × 10 8 parasites and 1 × 10 8 peritoneal macrophages, respectively, under the same experimental conditions used to extract the samples. Reactions were processed and analyzed in an ABI Prism 7500 Sequence Detection System (96 wells-plate; Applied Biosystems) using 2 × SYBR™ Select Master Mix (5 µL; Applied Biosystems), with 2 mM of each primer (1 µL) and 4 µL of DNA (25 ng/µL). Samples were incubated at 95 °C for 10 min, and submitted to 40 cycles of 95 °C for 15 s and 60 °C for 1 min. For each cycle, fluorescence data were collected. Results were calculated by interpolation from a calibration curve, which was run in parallel to the samples, performed in duplicate and expressed as the number of L. infantum organisms per total DNA.

ACA toxicity was evaluated in vivo in the treated and infected mice, by means of dosage of aspartate aminotransferase (AST), alanine aminotransferase (ALT), direct bilirubin and total bilirubin, which were used as hepatic damage markers, and of creatine kinase muscle brain fraction (CK-MB), which was used as cardiac damage marker. The analyses were performed using commercial kits (Labtest Diagnostica ® , Belo Horizonte) according to the manufacturer's instructions.

IC 50 , CC 50 and RBC 50 values were calculated by dose-response curves using Microsoft Excel software (version 10.0) and plotted in GraphPad Prism 5.03. Results were analyzed by one-way analysis of variance (ANOVA) followed by Bonferroni's post-test for comparison between the groups. Results were expressed as mean ± standard deviation for each group. Two independent experiments were performed and similar results were observed. Differences were considered significant when P < 0.05.

ACA antileishmanial activity was evaluated in vitro against L. infantum species. AmpB was used as a control drug. Results showed IC 50 values of 0.47 ± 0.1 and 0.11 ± 0.03 µg/mL when ACA and AmpB were used, respectively (Table 1) . CC 50 and RBC 50 values were 265.4 ± 16.5 µg/mL and 454.6 ± 13.4 µg/mL for ACA, and 0.92 ± 0.13 µg/mL and 12.2 ± 1.6 µg/mL for AmpB, respectively, with corresponding Selectivity Index values of 564.7 and 8.4. Treatment of infected macrophages showed infectiveness reduction of 87.4% and 67.5% when ACA and AmpB were used at concentrations of 10.0 and 1.0 µg/mL, respectively ( Table 2 ). Inhibition of infection using pre-treated parasites showed similar infectiveness reduction levels of 87.7% (ACA) and 73.3% (AmpB) ( Table 3) .

The proof of concept for the mechanism of action of ACA as an inhibitory drug was evaluated in L. infantum. Results showed that the molecule induced 36.9% and 33.6% reduction in the parasite' mitochondrial membrane potential (ΔΨm) when used at concentrations of 0.35 and 0.70 µg/mL, respectively (Fig. 1a) . FCCP-treated parasites used as control presented 47.7% reduction. Induction of oxidative stress was also observed in ACA-treated parasites, which was reflected by a 92.9% and 124.1% increase in reactive oxygen species (ROS) production when ACA was used at concentrations of 0.35 and 0.70 µg/mL, respectively (Fig. 1b) . H 2 O 2 -treated parasites, used as a positive control, showed an increase in ROS production of 145.6%. Furthermore, treatment with ACA (0.35 and Table 1 In vitro biological activity L. infantum stationary promastigotes were incubated with ACA (0-100 µg/mL) or AmpB (0-10.0 µg/mL) for 48 h at 24 °C. Cell viability was analyzed by MTT method and 50% Leishmania inhibitory concentration (IC 50 ) was calculated by sigmoidal regression of the corresponding dose-response curve. Similarly, murine macrophages were incubated with ACA (0-100 µg/mL) or AmpB (0-10.0 µg/mL), and 50% macrophage inhibitory concentration (CC 50 ) was determined by sigmoidal regression of the corresponding dose-response curve. Selectivity index (SI) was calculated as the ratio between CC 50 and IC 50 values. 50% inhibition of human red cells (RBC 50 ) viability was calculated by incubating a 5% red cells suspension with ACA (0-100.0 µg/mL) or AmpB (0-10.0 µg/mL) for 1 h at 37 °C in 5% CO 2 . Lysis percentage was evaluated spectrophotometrically, and the absence (blank) or 100% of hemolysis were determined by replacing ACA for an equal volume of PBS or distilled water, respectively. Results are expressed as mean ± standard deviation 0.70 µg/mL) induced a significant increase in the accumulation of lipid bodies in the order of 55.9% and 87.0%, respectively (Fig. 2) .

Anti-Leishmania humoral response of infected and treated mice was evaluated one and 15 days post-therapy. Results showed that Miltefosine, ACA or ACA/Mic-treated mice presented significantly higher levels of anti-parasite IgG2a antibody when compared to IgG1 levels. On the contrary, saline-and B/Mic-treated groups produced significantly higher levels of antileishmanial IgG1 antibody (Fig. 3) . Similar results were observed one and 15 days post-therapy, suggesting the development of a sustained humoral response profile after treatment of infection.

Cellular response of infected and treated mice was evaluated one and 15 days post-treatment by means of dosage of Th1 and Th2-type profile cytokines. Results obtained one day after treatment showed that spleen cells from Miltefosine, ACA or ACA/Mic-treated mice produced significantly higher levels of IFN-γ, IL-12 and GM-CSF, as well as low IL-4 and IL-10 levels. On the other hand, saline-and B/Mictreated mice groups produced significantly higher levels of antileishmanial IL-4 and IL-10 cytokines (Fig. 4) . Nitrite production was also evaluated in the cell supernatant, and results showed that treatment with Miltefosine, ACA or ACA/Mic induced increased levels of this molecule, when compared to the control groups (Fig. 5) . To evaluate the participation of T cells in the IFN-γ production in the Miltefosine-, ACA-or ACA/Mic-treated mice, anti-CD4 and anti-CD8 monoclonal antibodies were separately added to the in vitro cultures when stimulus using SLA was performed. Results showed reductions in the levels of this cytokine in the evaluated animals, when compared to the IFN-γ values found in the cell supernatant of stimulated cultures but nonincubated with the monoclonal antibodies; suggesting then that both CD4 + and CD8 + T cells were important for the IFN-γ production in these treated animals (Fig. 6) . A flow cytometry assay showed also that Miltefosine-, ACA-or ACA/Mic-treated mice presented significantly higher levels of IFN-γ-and TNF-α-producing CD4 + and CD8 + T cells, when compared to the controls. Conversely, mice groups receiving saline or B/Mic presented significantly higher IL-10-producing CD4 + T cell levels (Fig. 7) .

To evaluate parasitological efficacy of therapeutics, the parasite load in infected and treated animals was analyzed in two different periods of time post-treatment. In both cases, results showed that Miltefosine-, ACA-or ACA/Mic-treated mice presented significant reductions in the parasite percentage in their livers, spleens, BMs and dLNs when compared to the untreated and infected group mice (Fig. 8) . One day post-therapy, mice groups receiving Miltefosine, ACA or ACA/Mic presented reductions in the parasite percentage in the order of 60.0%, 65.0% and 80.0%, respectively, in their spleens; of 42.9%, 50.0% and 78.6%, respectively, in their livers; of 54.5%, 63.6% and 77.3%, respectively, in their dLNs; and of 41.7%, 50.0% and 75.0%, respectively, in their BMs, when compared to the saline group. Fifteen days post-treatment, reductions in the parasite percentage in Miltefosine-, ACA-and ACA/Mic-treated mice were of 54.5%, 63.6% and 77.3%, respectively, in their spleens; of 43.7%, 50.0% and 75.0%, respectively, in their livers; of 45.8%, 62.5% and 70.8%, respectively, in their dLNs; and of 42.9%, 50.0% and 64.3%, respectively, in their BMs, when compared to the saline group. The splenic parasite load was also evaluated by qPCR technique, and results showed reductions in the parasite percentage in Miltefosine-, ACAand ACA/Mic-treated mice in the order of 46.7%, 63.0% and 77.0%, respectively, when compared to the saline group (Fig. 9) . Importantly, ACA/Mic-treated group showed the highest reductions in the parasite percentage in the evaluated organs, when compared to the other experimental groups.

The hepatic and cardiac toxicity was evaluated after treatment. Results showed higher levels of these markers in control group mice. By comparison of the distinct treatment schedules, Miltefosine-treated mice presented a slight increase in AST, ALT, direct bilirubin, total bilirubin and CK-MB levels, when compared to mice groups treated with ACA or ACA/Mic (Fig. 10) . A comparison between these groups showed that micelles reduced the hepatic and cardiac toxicity attributed to ACA in the treated animals, showing values near to those found when sera samples of uninfected and untreated mice were used. 

Treatment against VL is toxic, expensive, lengthy and its efficacy is not warranted. In addition, parasite resistance to commonly used antileishmanial drugs has also been reported [9] . Thus, there is an urgent need to identify new antileishmanial targets. Discovery of new compounds is a long and expensive task, hence, drug repositioning or repurposing should be considered [1] . In the present study, we evaluated the potential antileishmanial activity of ACA, an approved drug for treating type-2-diabetes [22] , against L. infantum, main species responsible for most VL cases in the Americas [37] . We analyzed both in vitro and in vivo the possibility of repurposing ACA as a potential therapeutic agent against VL.

Miltefosine was used as a positive control drug for the experiments in vivo. This drug has long been effectively utilized as an orally administered agent for VL treatment [32, 49] . However, disease relapses and parasite resistance have been reported, mainly due to prolonged therapy durations and the drug presenting with a long half-life [33, 35, 43, 48] . In the present study, therapeutic action of Miltefosine was found to be satisfactory. However, treatment of L. infantum-infected mice with ACA, administered either in its free format or incorporated into a micelle delivery system, resulted in significantly lower parasite loads in spleen, liver, BM and dLN than when treating with Miltefosine, tested both by limiting dilution technique and qPCR. The lowest parasitism values were found when infected animals received ACA incorporated into the polymeric micelle system; suggesting this composition should Higher efficacy has been observed with antileishmanial agents, such as well-characterized AmpB or newer candidates, such as quinolines, flavonoids, among others, when administered within a delivery system [13, 46, 57] . In this report, and in agreement with other studies, incorporation of ACA into a Poloxamer 407-based micelle system resulted in a significantly better immunological and parasitological response than when using the free molecule. Similarly, Espuelas et al. [16] tested AmpB-coated polymeric micelles against L. donovani species, reporting a synergic action between the drug and the micellar composition, with increases in anti-parasite activity of up to 100 times, when compared to the use of the drug in its free form. In a more recent study, Singh et al. [45] used an AmpB-containing chitosan-coated Poloxamer 407 micelle system, and found that drug delivery within the micelles presented better antileishmanial activity and lower toxicity, in comparison to the use of the free drug. The authors reported the development of a more polarized Th1-type immune response, as well as higher reductions in parasite burden in L. donovani-infected and treated hamsters when compared to treatment with the free drug.

In the present study, Miltefosine-, ACA-or ACA/Mictreated mice developed a Th1-type immune response profile, characterized by significantly higher levels of IFN-γ, IL-12 and GM-CSF, as well as low IL-4 and IL-10 levels, than the corresponding controls. An in vitro assay using monoclonal antibodies to block T cell subtypes showed that both CD4 + and CD8 + T cell subtypes were responsible for IFN-γ production after treatment. This Th1-type response was related also to the induction of nitrite production by stimulated spleen cells of infected and treated animals, suggesting activation of host macrophages to kill the parasite. Others have likewise shown the development of similar immune profiles in response to treatment of Leishmania-infected mice with antileishmanial molecules, evidencing their relevance for the mammalian host to combat the infection [11, 19, 41] .

With the aim to select novel, non-toxic antileishmanial agents, ACA toxicity was evaluated in vivo by means of biochemical dosage of hepatic and cardiac damage markers in sera samples collected from infected and treated animals. Results showed high levels of these enzymatic damage markers in control groups mice, while a slight increase was found in Miltefosine-treated mice when compared to data obtained in the ACA or ACA/Mic groups. In a similar fashion, others have showed also limitations to prolonged usage of Miltefosine related to organic side-effects [5, 18, 47] . Our results showed that treatment with ACA-containing Fig. 10 Evaluation of toxicity in vivo. Levels of creatine kinase muscle brain fraction (CK-MB; in a) alanine aminotransferase (ALT; in b), aspartate aminotransferase (AST; in c), direct bilirubin (in d) and total bilirubin (in e) were measured in sera samples collected from treated and infected mice, one and 15 days post-therapy. Sera samples of naive (uninfected and untreated) mice were used as control. Bars indicate the mean ± standard deviation of the groups. (*) indicate statistically significant difference in relation to the saline and B/Mic groups (P < 0.05). (**) indicate statistically significant difference in relation to the Miltefosine group (P < 0.05). (***) indicate statistically significant difference in relation to the ACA group (P < 0.05) micelles was not toxic to the host and thus, suggest ACA/ Mic formulation as a promising replacement for a safer treatment against VL.

Leishmania mitochondria is a primary target for therapeutic candidates since it is intimately related to the parasite's metabolism and signaling pathways, such as ATP production, regulation of antioxidant machinery, maintenance of ionic homeostasis and special sterol composition [17] . In our study, treatment with ACA resulted in impairment of L. infantum mitochondrial function, causing a disturbance in the mitochondrial membrane potential and a significant increase in ROS production. In addition, ACA caused also the formation and accumulation of lipid bodies in the parasites. Since lipid droplets are related to organelles that regulate the storage of neutral lipids, composed of triacylglycerols and sterol esters [30] , this observation could imply cellular stress [26, 40, 44] . Concordantly, treatment with ACA significantly increased the levels of neutral lipids, suggesting the occurrence of cell disorders followed by parasite death. Despite the fact that preliminary results imply ACA targets the Leishmania mitochondria, additional studies are certainly necessary to confirm its mechanism of action.

Limitations of this study include the absence of an evaluation of therapeutic efficacy at different time points posttreatment, as well as the lack of comparison of different dose schedules. This point will be relevant, mainly due to reports of hepatoxicity caused by ACA in humans [8, 23] . In this context, lower doses of this drug, when incorporated in micelles as a delivery system, could help to reach maximum antileishmanial effect but minimum organ toxicity in treated hosts. As a consequence, additional studies are necessary to be performed aiming to solve this question. Nevertheless, the data here presented suggest both in vitro and in vivo antileishmanial activity of ACA against L. infantum, mainly when administered within Pluronic ® F127-based polymeric micelles. Results showed specific production of Th1-type cytokines, with consequential significant reduction of parasitism in distinct organs. In conclusion, ACA/Mic is a promising candidate drug which merits further consideration in future studies for VL treatment advancement.

Leishmaniasis treatment: update of possibilities for drug repurposing

Antileishmanial activity of a 4-hydrazinoquinoline derivative: induction of autophagy and apoptosis-related processes and effectiveness in experimental cutaneous leishmaniasis

A real-time PCR assay for quantification of parasite burden in murine models of leishmaniasis

Early clinical manifestations associated with death from visceral leishmaniasis

Phase-4 trial of miltefosine for the treatment of Indian visceral leishmaniasis

Chimeric vaccines designed by immunoinformatics-activated polyfunctional and memory T cells that trigger protection

Acarbose-induced acute severe hepatotoxicity

Current and emerging medications for the treatment of leishmaniasis

In silico Leishmania proteome mining applied to identify drug target potential to be used to treat against visceral and tegumentary leishmaniasis

Leishmanicidal activity of Piper nigrum bioactive fractions is interceded via apoptosis in vitro and substantiated by Th1 immunostimulatory potential in vivo

Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection

Preclinical studies evaluating subacute toxicity and therapeutic efficacy of LQB-118 in experimental visceral leishmaniasis

Cytokines: key determinants of resistance or disease progression in visceral leishmaniasis: opportunities for novel diagnostics and immunotherapy

Treatment of murine visceral leishmaniasis using an 8-hydroxyquinoline-containing polymeric micelle system

In vitro reversion of amphotericin B resistance in Leishmaniadonovani by Poloxamer 188

Mitochondria and trypanosomatids: targets and drugs

Leishmaniasis revisited: current aspects on epidemiology, diagnosis and treatment

Vitamins (A&D) and isoprenoid (Chenodeoxycholic acid) molecules are accompanied by Th1 immunostimulatory response and therapeutic cure in vivo: possible antileishmanial drugs

Leishmaniases of the New World: current concepts and implications for future research

Acarbose: oral anti-diabetes drug with additional cardiovascular benefits

Safety and efficacy of acarbose in the treatment of diabetes in Chinese patients

Hepatotoxicity associated with acarbose therapy

Immune responses during cutaneous and visceral leishmaniasis

An 8-hydroxyquinoline-containing polymeric micelle system is effective for the treatment of murine tegumentary leishmaniasis

Potent in vitro antiproliferative synergism of combinations of ergosterol biosynthesis inhibitors against Leishmania amazonensis

Pharmacokinetics, safety, and efficacy of an allometric miltefosine regimen for the treatment of visceral leishmaniasis in Eastern African children: an open-label, phase II clinical trial

Comparing the therapeutic efficacy of different amphotericin B-carrying delivery systems against visceral leishmaniasis

In vivo antileishmanial efficacy of a naphthoquinone derivate incorporated into a Pluronic ® F127-based polymeric micelle system against Leishmania amazonensis infection

The photodynamic action of pheophorbide a induces cell death through oxidative stress in Leishmania amazonensis

Recent advances in development of amphotericin B formulations for the treatment of visceral leishmaniasis

Miltefosine for visceral and cutaneous leishmaniasis: drug characteristics and evidence-based treatment recommendations

Pharmacovigilance of miltefosine in treatment of visceral leishmaniasis in endemic areas of Bihar, India

Pluronic ® P123/ F127 mixed micelles delivering Sorafenib and its combination with Verteporfin in cancer cells

Mechanisms of experimental resistance of Leishmania to miltefosine: implications for clinical use

The safety and efficacy of miltefosine in the long-term treatment of post-kalaazar dermal leishmaniasis in South Asia-a review and metaanalysis

Geographical distribution and epidemiological features of Old World Leishmania infantum and Leishmaniadonovani foci, based on the isoenzyme analysis of 2277 strains

Safety and efficacy of short course combination regimens with Am Bisome ® , miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh

Eugenol derived immunomodulatory molecules against visceral leishmaniasis

Lopinavir, an HIV-1 peptidase inhibitor, induces alteration on the lipid metabolism of Leishmaniaamazonensis promastigotes

Antiparasitic effect of synthetic aromathecins on Leishmania infantum

Ivermectin presents effective and selective antileishmanial activity in vitro and in vivo against Leishmania infantum and is therapeutic against visceral leishmaniasis

Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance

Primary evidence of the mechanisms of action of HIV aspartyl peptidase inhibitors on Trypanosoma cruzi trypomastigote forms

Chitosan coated Pluronic F127 micelles for effective delivery of amphotericin B in experimental visceral leishmaniasis

A chloroquinoline derivate presents effective in vitro and in vivo antileishmanial activity against Leishmania species that cause tegumentary and visceral leishmaniasis

Miltefosine in the treatment of leishmaniasis. Clinical evidence for informed clinical risk management

Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use

Efficacy and safety of miltefosine in treatment of post-kala-azar dermal leishmaniasis

Chemotherapeutics of visceral leishmaniasis: present and future developments

Effectiveness of single-dose liposomal amphotericin B in visceral leishmaniasis in Bihar

Antileishmanial activity, cytotoxicity and mechanism of action of clioquinol against Leishmania infantum and Leishmaniaamazonensis species

A Pluronic ® F127-based polymeric micelle system containing an antileishmanial molecule is immunotherapeutic and effective in the treatment against Leishmania amazonensis infection

A clioquinol-containing Pluronic ® F127 polymeric micelle system is effective in the treatment of visceral leishmaniasis in a murine model

Novel arylimidamides for treatment of visceral leishmaniasis

Synthesis and biological evaluation of ferrocenylquinoline as a potential antileishmanial agent

Leishmania parasitophorous vacuole membranes display phosphoinositides that create conditions for continuous Akt activation and a target for miltefosine in Leishmania infections

Synthesis and pharmacological evaluation of mono-arylimidamides as antileishmanial agents

The authors confirm that they have no conflicts of interest in relation to this work.